AVLN Avalyn Pharma (AVLN) Insider Trading, Ownership & Congress Trades
Pharma & Biotech · Pharmaceutical preparations · CIK 0001540171
Cluster · 3 insidersActivist 13D
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
95
13F, latest reported quarter
Conversions, 180 days
12
Codes C/M, not in net · no price filed
What the filings say about AVLN
Insiders, 180 days
+$25.0M net bought
3 buyers
Activist stakes (13D), 180 days
2 filings
Largest: 7.5% of the class
Avalyn Pharma insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, Avalyn Pharma Inc. insiders bought a net $25.0M of stock across 4 Form 4 purchases and sales, with 3 insiders buying. Source: SEC Form 4 filings, as of 2026-10-27.
Insider
Filed
Shares
Value
Since filing
Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 14.3% of the 3,883,289 shares held after it.
- 2 other insiders bought within 30 days.
- 95 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider Novo Holdings A/S bought about $10.0M of AVLN on May 1, 2026, the largest insider purchase at the company on our record; 2 other insiders bought within 30 days and 95 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 12.7% of the 2,186,562 shares held after it.
- 2 other insiders bought within 30 days.
- 95 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Carroll Jill bought about $5.0M of AVLN on May 1, 2026, the largest insider purchase at the company on our record; 2 other insiders bought within 30 days and 95 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 24.8% of the 1,122,087 shares held after it.
- 2 other insiders bought within 30 days.
- 95 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider George Simeon bought about $5.0M of AVLN on May 1, 2026, the largest insider purchase at the company on our record; 2 other insiders bought within 30 days and 95 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 12.7% of the 2,186,562 shares held after it.
- 2 other insiders bought within 30 days.
- 95 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider George Simeon bought about $5.0M of AVLN on May 1, 2026, the largest insider purchase at the company on our record; 2 other insiders bought within 30 days and 95 funds added in the latest 13F quarter.4 transactions on record · a thin record, read with care
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net +$25.0M over 180 days
+$20.0M of it by a 10%+ holder
more than 97% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
95 funds bought in last quarter
more than 66% of Pharma & Biotech
Revenue
no revenue reported in any filing
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
9.2% of the float short (float per yahoo 2026-10-26) · 8.5 days to cover · settled 2026-09-30
more than 54% of Pharma & Biotech
The situation: each line is one rule over one dataset
SUVRETTA CAPITAL MANAGEMENT, LLC disclosed a 5%+ stake (5.6%) in the last six months.
What changed in the last 30 days
Oct 27Insider buying stopped: no purchases in 90 days after 4 in the prior 90
Why it matters
The absence is the signal: 4 purchases in one 90-day window and none in the next is a change of behaviour, not a filing.
Watch AVLN
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-8.0%12M
Insider buy13D/G stake
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns AVLN: institutional holders (13F)
13F holdings, latest reported quarter
5,835,259 sh
$192.1M
3,883,289 sh
$127.8M
3,308,649 sh
$108.9M
2,675,296 sh
$88.1M
2,503,109 sh
$82.4M
Congress trades in AVLN
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
13D: intends to influence · 13G: passive
SUVRETTA CAPITAL MANAGEMENT, LLC
Activist 13D · 2026-05-08
5.6%
Averill Master Fund, Ltd.
Activist 13D · 2026-05-08
4.9%
Averill Madison Master Fund, Ltd.
Activist 13D · 2026-05-08
0.7%
Aaron Cowen
Activist 13D · 2026-05-08
5.6%
SR One Capital Management, LLC
Activist 13D · 2026-05-08
7.5%
AVLN planned insider sales (Form 144)
No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
AVLN mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
PGIM Jennison Health Sciences Fund
$9.2M position · as of 2026-05-29
0.7%
Fidelity Small Cap Growth Fund
$35.5M position · as of 2026-07-31
0.4%
Fidelity Small Cap Growth K6 Fund
$18.1M position · as of 2026-07-31
0.4%
Franklin Biotechnology Discovery Fund
$3.5M position · as of 2026-07-31
0.3%
Fidelity Advisor Biotechnology Fund
$4.7M position · as of 2026-07-31
0.2%
Eventide Healthcare & Life Sciences Fund
$3.3M position · as of 2026-06-30
0.2%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Clinical pipeline
3 registered trials, 3 still running (ClinicalTrials.gov).
A status change is dated here weeks before the press release.
3
Phase 2
3 active
Matched by sponsor name. Trials run under a subsidiary's
own name are not included.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
3 insiders reported buying shares.
The record shows a net $25.0M bought by insiders over 180 days, 95 funds added last quarter. Each figure is a federal filing, dated the day it went public.
AVLN financials
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
n/a
fewer than four consecutive quarters of revenue filed
Revenue, TTM AVLN
| none filed |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
At each fiscal year end
Single quarter
Net margin, TTM
n/a
needs four consecutive quarters of both revenue and net income
Net margin, TTM AVLN
| none filed |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
At each fiscal year end
Single quarter
Free cash flow, TTM
n/a
fewer than four consecutive quarters of operating cash flow
Free cash flow, TTM AVLN
| none filed |
| Jun 2026 | -$26.3M |
| Mar 2026 | -$30.2M |
| Jun 2025 | -$20.7M |
| Mar 2025 | -$19.3M |
At each fiscal year end
Single quarter
Debt to equity
0.04x
long-term debt only, 2026-06-30; equity 2026-06-30
Debt to equity AVLN
| none filed |
| Jun 2026 | 0.04x |
| Mar 2026 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
n/a
needs four quarters of operating cash flow
Cash flow to debt AVLN
| none filed |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
n/a
fewer than four consecutive quarters of net income
Return on equity AVLN
| none filed |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
n/a
fewer than four consecutive quarters of net income
Return on assets AVLN
| none filed |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
fewer than four consecutive quarters of operating income
Return on invested capital AVLN
| none filed |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
n/a
fewer than four consecutive quarters of operating income
Return on capital employed AVLN
| none filed |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
fewer than four consecutive quarters of diluted EPS
P/E, trailing AVLN
| none filed |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$953.8M
market value at close 2026-10-26 on 2026-08-31 shares, plus long-term debt only, 2026-06-30, minus cash 2026-06-30
Enterprise value AVLN
| none filed |
| Jun 2026 | $1.2B |
| Mar 2026 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
n/a
fewer than four consecutive quarters of operating cash flow
FCF yield AVLN
| none filed |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
fewer than four consecutive quarters of diluted EPS
PEG, trailing AVLN
| none filed |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
AVLN Stock Sonar score 4/7 axes
Find similar shapesCompareAVLN ranks highest on insider conviction (93rd percentile) and financial health (66th), and lowest on risk and compliance (41st), among Pharma & Biotech peers.
4 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
AVLN filings, in plain words
Are Avalyn Pharma insiders buying or selling AVLN?
In the 180 days to 2026-10-27, Avalyn Pharma insiders were net buyers, a net $25.0M across purchases and sales reported on Form 4, by 3 buyers.
Read the full summary
In the 180 days to 2026-10-27, Avalyn Pharma insiders were net buyers of AVLN, a net $25.0M across purchases and sales reported on Form 4 by 3 buyers. Most of that figure, $20.0M, came from a holder of 10% or more rather than an officer or director. 3 insiders reported purchases in that window. 2 activist Schedule 13D filings in the last 180 days declared an intent to influence the company, the largest for 7.5% of the class. Each figure is counted from SEC and House filings as of 2026-10-27, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
